If you or a loved one is taking Tysabri, you may wonder how PML risk evolves over time—both during treatment and after stopping. The legacy of medical research on biologic therapies has long emphasized the need for ongoing safety surveillance, and this page outlines the documented timeline of PML onset to help you understand the monitoring milestones.
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Illinois who have developed PML after Tysabri treatment, understanding the medical evidence and legal considerations—including the statute of limitations—is critical. PML is an opportunistic viral infection of the brain caused by the JC virus that typically occurs only in immunocompromised patients and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Tysabri increases the risk of PML, as stated in the drug's boxed warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three established risk factors for PML in Tysabri-treated patients are: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing treatment, weighing expected benefit against PML risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical presentation of PML can include progressive neurological deficits such as weakness, vision changes, cognitive decline, and coordination problems. Diagnosis typically involves MRI imaging and detection of JC virus DNA in cerebrospinal fluid. Because PML can be rapidly progressive, early recognition is essential. The prescribing information instructs healthcare professionals to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first such sign (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, cases have occurred, and the outcome is often fatal or leads to severe disability.
The mechanistic link between Tysabri and PML involves the drug's action as an alpha-4 integrin antagonist. Tysabri blocks lymphocyte adhesion and migration across the blood-brain barrier, reducing immune surveillance in the central nervous system. This immunosuppressive effect allows latent JC virus to reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the characteristic lesions of PML. The risk is amplified in patients with anti-JCV antibodies, indicating prior exposure to the virus, and with prolonged treatment duration. Tysabri carries a boxed warning that clearly states the increased risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The drug is only available through a restricted distribution program called the TOUCH Prescribing Program, which requires patients to read a Medication Guide, understand the risks, and sign an enrollment form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Pharmacies and infusion centers must be specially certified to dispense or infuse Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, questions may arise about whether warnings were adequately communicated to individual patients, particularly regarding the magnitude of risk and the need for ongoing monitoring. For affected patients in Illinois, the adequacy of warnings is a central issue in any legal claim.
For patients who have developed PML after Tysabri treatment, settlement considerations include the severity of injury, medical expenses, lost income, and pain and suffering. The timeline between Tysabri exposure and documented harm is critical: PML typically occurs after months to years of treatment, with risk increasing beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This latency period can complicate legal claims, as the statute of limitations in Illinois for personal injury actions is generally two years from the date the injury was discovered or should have been discovered. For PML, the "discovery rule" may apply, meaning the clock starts when the patient knew or reasonably should have known that Tysabri caused the harm. Given the insidious onset of PML symptoms, this date may be difficult to pinpoint. Patients and their families should consult with an attorney experienced in pharmaceutical litigation to determine whether their claim falls within the applicable time frame. In summary, Tysabri-associated PML is a devastating condition with well-defined risk factors and a clear mechanistic basis. While the drug's labeling includes prominent warnings, affected patients in Illinois face complex medical and legal issues, including the statute of limitations. Early legal consultation is advisable to preserve potential claims.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Illinois, the statute of limitations for personal injury actions is generally two years from the date the injury was discovered or should have been discovered. For PML, the discovery rule may apply, meaning the clock starts when the patient knew or reasonably should have known that Tysabri caused the harm. Given the insidious onset of PML symptoms, this date can be difficult to determine. Consulting an attorney experienced in pharmaceutical litigation is strongly recommended.
Three established risk factors for PML in Tysabri-treated patients are: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing treatment.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented Tysabri exposure and a related diagnosis may request an independent, no-cost eligibility review.